Courtesy of Dr. Carlos Fava. Moderate/severe paravalvular regurgitation (PVR) after TAVR is present in 10%-14% of all cases, according to different series. The treatment of choice is post-dilation, generally effective in most cases. However, this strategy carries a risk of stroke. The true impact of this conduct is still unclear. This review analyzed 6 studies that included 5007 patients; 889 of<a href="https://solaci.org/en/2017/07/10/post-dilation-in-tavi-associated-to-more-stroke-and-more-paravalvular-regurgitation/" title="Read more" >...</a>
Critical ischemia in the lower limbs: Frequent Readmissions show the magnitude of this problem
Readmissions at 6 months in patients with critical ischemia in the lower limbs occur in about 50% of all cases and most of them are unplanned. This truly alarming number is cause for further concern when taking into account that only part of these readmissions are related to vascular problems. Many are caused by comorbidities<a href="https://solaci.org/en/2017/07/05/critical-ischemia-in-the-lower-limbs-frequent-readmissions-show-the-magnitude-of-this-problem/" title="Read more" >...</a>
Less volume, more mortality: should we be concerned?
Courtesy of Dr. Agustín Vecchia. In general, guidelines recommend a number of procedures a year for operators to maintain a reasonably safe level of proficiency. Even though this number is arbitrary and operators’ aptitude varies considerable, more than one publication has found an inverse correlation between procedure volume and outcomes. This study incorporated 10,496 operators<a href="https://solaci.org/en/2017/06/30/less-volume-more-mortality-should-we-be-concerned/" title="Read more" >...</a>
The transradial approach reduces the risk of kidney injury in acute patients
It remains unclear whether transradial access, compared with transfemoral access, presents a different risk of post-procedural kidney injury for patients admitted with acute coronary syndrome. Historically, it has been considered (without any evidence) that, given the higher difficulty associated with transradial access, it would require longer fluoroscopy time and higher contrast volume, which would eventually<a href="https://solaci.org/en/2017/06/21/the-transradial-approach-reduces-the-risk-of-kidney-injury-in-acute-patients/" title="Read more" >...</a>
Everolimus DES are more effective and less costly than conventional BMS
Courtesy of Dr. Guillermo Migliaro. Drug eluting stents (DES) represented the greatest technological advance in the treatment of instent restenosis from conventional metallic stents (BMS), especially cobalt chromium everolimus eluting stents (CoCr EES), which have shown an excellent profile, and are mostly safer, compared to first generation DES. Indeed, several randomized studies and meta-analyzis have<a href="https://solaci.org/en/2017/06/16/everolimus-des-are-more-effective-and-less-costly-than-conventional-bms/" title="Read more" >...</a>
TAVR presents less post-procedural MI than surgical aortic valve replacement
Courtesy of Dr. Carlos Fava. Surgical aortic valve replacement (SAVR) continues to be elective, but the presence of post-procedural acute myocardial infarction (AMI) has been associated to bad evolution. Despite the proven benefits of TAVR for high risk patients and the progress shown by patients of intermediate risk, the incidence of post implantation MI has<a href="https://solaci.org/en/2017/06/13/tavr-presents-less-post-procedural-mi-than-surgical-aortic-valve-replacement/" title="Read more" >...</a>
Are 7 Fr Dedicated Transradial Introducers Safe?
Courtesy of Dr. Carlos Fava. The transradial approach has been proven beneficial for quite some time now, but certain scenarios require the use of a 7 Fr or 8 Fr introducer, which is a great limitation. This study included 60 patients who underwent complex angioplasty with the help of 7 Fr dedicated transradial (TR) introducer Glidesheath Slender (Terumo, Tokyo,<a href="https://solaci.org/en/2017/06/06/are-7-fr-dedicated-transradial-introducers-safe/" title="Read more" >...</a>
Amplatzer and Figulla Devices Prove to Be Safe for Percutaneous Patent Foramen Ovale Closure
Courtesy of Dr. José Álvarez. In patients with presumed paradoxical embolism through a patent foramen ovale (PFO) who are at high risk of recurrent thromboembolic events, percutaneous PFO closure is an alternative to pharmacological treatment. This closure has been shown to be safe and feasible with different devices including various technologies based on an umbrella,<a href="https://solaci.org/en/2017/05/30/amplatzer-and-figulla-devices-prove-to-be-safe-for-percutaneous-patent-foramen-ovale-closure/" title="Read more" >...</a>
[SURTAVI] Sub-study of neurological events: more evidence in favor of TAVR
Courtesy of SBHCI. The occurrence of a periprocedural neurological events is associated to an increased risk of death and morbidity at long term, both for transcatheter aortic valve replacement (TAVR) and for surgery. The SURTAVI study, recently presented at the ACC meeting and simultaneously published by NEJM, showed that TAVR with self-expandable CoreValve or Evolut<a href="https://solaci.org/en/2017/05/30/surtavi-sub-study-of-neurological-events-more-evidence-in-favor-of-tavr/" title="Read more" >...</a>
Mitral Valve Global Registry: transcatheter mitral valve replacement due to native valve disease
Courtesy of the SBHCI. The risk of surgical mitral valve replacement in patients with significant annular calcification is very high. There are isolated reports of transcatheter mitral valve replacement with balloon-expandable valve in this patient population. In consequence, this multicenter registry tries to concentrate information and analyzes the outcomes a year after the procedure. <a href="https://solaci.org/en/2017/05/30/mitral-valve-global-registry-transcatheter-mitral-valve-replacement-due-to-native-valve-disease/" title="Read more" >...</a>